Loading people...
Kim P. Kamdar is a Partner at Domain Associates, a leading venture capital firm focused on the life sciences sector. She is known for her expertise in identifying and investing in innovative biotechnology and medical device companies.
Kim P. Kamdar primarily invests in early-stage life science companies. Her focus areas include novel therapeutics, advanced diagnostics, and innovative medical devices, often within fields like oncology, immunology, and rare diseases.
Kim P. Kamdar works as a Partner at Domain Associates, a prominent venture capital firm with a strong emphasis on the life sciences industry.
Kim P. Kamdar is a Partner at Domain Associates based in San Diego, California, where she specializes in early-stage life sciences and healthcare investments. She joined the venture capital firm in 2005 and became a partner in 2011, following her tenure as a research director at Novartis leading small molecule discovery teams. Kamdar has guided multiple portfolio companies toward successful exits, including the acquisitions of Ariosa Diagnostics by Roche and Corthera by Novartis. She currently serves as Board Chair for Sera Prognostics, which completed its initial public offering in 2021, and acts as co-founder and Chair of Truvian Sciences, helping secure its $105 million Series C funding. Equipped with a doctorate in biochemistry and genetics from Emory University and seven patents, Kamdar focuses on translating scientific breakthroughs into commercial therapeutics and molecular diagnostics.
Kim P. Kamdar stands as a highly respected Partner at Domain Associates, a leading venture capital firm renowned for its deep expertise in the life sciences sector. With a career dedicated to fostering groundbreaking innovation, Ms. Kamdar plays a pivotal role in identifying, evaluating, and supporting promising biotechnology and medical technology companies. Her strategic insights and extensive industry knowledge are instrumental in guiding portfolio companies from their nascent stages through significant growth and market entry.
At Domain Associates, Kim P. Kamdar's responsibilities encompass the full spectrum of venture capital activities. She is actively involved in deal sourcing, due diligence, and investment execution. Beyond capital deployment, she serves as a crucial board member and advisor to numerous portfolio companies, leveraging her operational experience and scientific acumen to help management teams navigate complex R&D challenges, regulatory pathways, and commercialization strategies. Her commitment extends to building strong leadership teams and fostering a culture of innovation within the companies she supports.
Ms. Kamdar's investment focus is sharply defined within the dynamic life sciences landscape. She primarily targets companies developing novel therapeutics, advanced diagnostics, and innovative medical devices that address significant unmet medical needs. Her portfolio often includes ventures in areas such as oncology, immunology, neuroscience, and rare diseases, reflecting a keen eye for scientific rigor and commercial potential. She is particularly interested in early-stage companies with disruptive technologies and strong intellectual property, believing in the transformative power of science to improve human health.
Prior to her distinguished career in venture capital, Kim P. Kamdar built a robust foundation in both scientific research and business development. She holds a Ph.D. in Biochemistry and Molecular Biology, providing her with a profound understanding of the scientific underpinnings of her investments. Her early career included roles in research and development, where she gained firsthand experience in drug discovery and development processes. This unique blend of scientific expertise and business acumen makes her an invaluable asset to both Domain Associates and its portfolio companies. Her journey into venture capital was a natural progression, allowing her to combine her passion for science with her strategic business insights to accelerate medical breakthroughs.
Throughout her tenure, Ms. Kamdar has been associated with numerous successful investments that have brought significant advancements to patient care and generated substantial returns for investors. While specific individual investments are proprietary, her track record reflects a consistent ability to identify companies poised for success, often leading to successful exits through acquisitions or initial public offerings. Her investment philosophy emphasizes rigorous scientific validation, strong management teams, and a clear path to market. Kim P. Kamdar continues to be a driving force in the life sciences venture capital community, dedicated to funding the next generation of medical innovation.
